rapidmicrobiology media kit in Chinese

« Previous article
CDC Report Shows Dec...

3rd February 2015  Content supplied by: Vivione Biosciences

Trillium Diagnostics Sold to Vivione Biosciences

Vivione Biosciences Inc. is to acquire all of the capital stock of Trillium Diagnostics for US$1.5 million in cash and US$4 million in common shares of Vivione at closing along with subsequent milestone-related.

Trillium is involved in the emerging area of immune-profiling that brings the approach of personalized medicine to infectious disease and sepsis diagnostics.Trillium's lead product, Leuko64, is a quantitative test for neutrophil CD64 expression, a marker directly associated with sepsis diagnosis.



Date Published: 3rd February 2015

Source article link: View

View full company details